RETRACTED: Astragaloside IV protects cardiomyocytes from hypoxia-induced injury by down-regulation of lncRNA GAS5

Biomed Pharmacother. 2019 Aug:116:109028. doi: 10.1016/j.biopha.2019.109028. Epub 2019 May 25.

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor-in-Chief. Concerns were raised about the background pattern of the Western Blots from Figures 1B and 1E. Given the comments of Dr Elisabeth Bik regarding this article “This paper belongs to a set of over 400 papers (as per February 2020) that share very similar Western blots with tadpole-like shaped bands, the same background pattern, and striking similarities in title structures, paper layout, bar graph design, and - in a subset - flow cytometry panels”, the journal requested the authors to provide the raw data. However, the authors were not able to provide raw data of sufficient quality and detail for the journal to independently audit the provenance and validity of the data, and therefore the Editor-in-Chief decided to retract the article.

Keywords: Astragaloside IV; Heart failure; Hypoxia injury; PI3K/mTOR; lncRNA GAS5.

Publication types

  • Retracted Publication

MeSH terms

  • Animals
  • Cardiotonic Agents / pharmacology*
  • Cell Line
  • Down-Regulation / drug effects*
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • Myocytes, Cardiac / pathology*
  • Phosphatidylinositol 3-Kinases / metabolism
  • RNA, Long Noncoding / genetics*
  • RNA, Long Noncoding / metabolism
  • Rats
  • Saponins / pharmacology*
  • TOR Serine-Threonine Kinases / metabolism
  • Triterpenes / pharmacology*

Substances

  • Cardiotonic Agents
  • RNA, Long Noncoding
  • Saponins
  • Triterpenes
  • astragaloside A
  • TOR Serine-Threonine Kinases